Literature DB >> 11596663

Antioxidants attenuate early up regulation of retinal vascular endothelial growth factor in streptozotocin-diabetic rats.

I G Obrosova1, A G Minchenko, V Marinescu, L Fathallah, A Kennedy, C M Stockert, R N Frank, M J Stevens.   

Abstract

AIMS/HYPOTHESIS: A strong positive correlation has been found between lipid peroxidation product and vascular endothelial growth factor concentrations in the vitreous of patients with proliferative diabetic retinopathy. To establish a causal relation between diabetes-associated enhanced oxidative stress and vascular endothelial growth factor production, we evaluated two antioxidants, DL-alpha-lipoic acid and taurine, on retinal vascular endothelial growth factor protein and mRNA expression and on parameters of oxidative stress in streptozotocin-diabetic rats.
METHODS: Our experiments were on control rats and streptozotocin-diabetic rats with a 6-week duration of diabetes, treated with or without DL-alpha-lipoic acid (100 mg x kg(-1) x d(-1), i.p.) or taurine (1% in the diet) starting from induction of diabetes. Vascular endothelial growth factor protein in retinal homogenates was assessed by sandwich ELISA with an affinity-purified polyclonal antibody and vascular endothelial growth factor mRNA by ribonuclease protection assay. Retinal lipid peroxidation products i.e. malondialdehyde plus 4-hydroxyalkenals were quantified with N-methyl-2-phenylindole. Retinal reduced and oxidized glutathione, ascorbate, dehydroascorbate, and sorbitol pathway intermediates were measured spectrofluorometrically, and taurine by reverse-phase HPLC.
RESULTS: Vascular endothelial growth factor protein concentration (means +/- SD) was increased in diabetic rats compared with control rats (33+/-7 vs 19+/-5 pg/mg total protein, p < 0.01) This increase was attenuated by taurine (26+/-8, p < 0.05) and prevented by DL-alpha-lipoic acid (21+/-4, p < 0.01). Vascular endothelial growth factor mRNA abundance was reduced by 1.4-fold in diabetic rats compared with control rats and this decrease was attenuated but not completely prevented by both antioxidants. Malondialdehyde plus 4-hydroxyalkenal concentration was increased in diabetic rats compared with control rats, and both antioxidants arrested accumulation of lipid peroxidation products. Taurine, reduced glutathione, oxidized glutathione, ascorbate, dehydroascorbate and sorbitol pathway intermediate concentrations as well as oxidized glutathione/reduced glutathione and dehydroascorbate/ascorbate ratios were similar in control and diabetic rats treated with or without taurine. CONCLUSION/
INTERPRETATION: Oxidative stress is directly involved in up regulation of vascular endothelial growth factor protein in the retina during early diabetes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11596663     DOI: 10.1007/s001250100631

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  42 in total

1.  Aldose reductase inhibition counteracts nitrosative stress and poly(ADP-ribose) polymerase activation in diabetic rat kidney and high-glucose-exposed human mesangial cells.

Authors:  Viktor R Drel; Pal Pacher; Martin J Stevens; Irina G Obrosova
Journal:  Free Radic Biol Med       Date:  2006-01-31       Impact factor: 7.376

2.  Taurine reduces nitrosative stress and nitric oxide synthase expression in high glucose-exposed human Schwann cells.

Authors:  Trevor Askwith; Wei Zeng; Margaret C Eggo; Martin J Stevens
Journal:  Exp Neurol       Date:  2011-09-17       Impact factor: 5.330

3.  Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications.

Authors:  Irina G Obrosova; Pal Pacher; Csaba Szabó; Zsuzsanna Zsengeller; Hiroko Hirooka; Martin J Stevens; Mark A Yorek
Journal:  Diabetes       Date:  2005-01       Impact factor: 9.461

4.  Dietary taurine supplementation ameliorates diabetic retinopathy via anti-excitotoxicity of glutamate in streptozotocin-induced Sprague-Dawley rats.

Authors:  Xiaoping Yu; Zhaoxia Xu; Mantian Mi; Hongxia Xu; Jundong Zhu; Na Wei; Ka Chen; Qianyong Zhang; Kaihong Zeng; Jian Wang; Fang Chen; Yong Tang
Journal:  Neurochem Res       Date:  2007-08-31       Impact factor: 3.996

5.  Role of mitochondrial DNA damage in the development of diabetic retinopathy, and the metabolic memory phenomenon associated with its progression.

Authors:  Sally A Madsen-Bouterse; Ghulam Mohammad; Mamta Kanwar; Renu A Kowluru
Journal:  Antioxid Redox Signal       Date:  2010-09-15       Impact factor: 8.401

6.  Oxidative stress and dysregulation of the taurine transporter in high-glucose-exposed human Schwann cells: implications for pathogenesis of diabetic neuropathy.

Authors:  Trevor Askwith; Wei Zeng; Margaret C Eggo; Martin J Stevens
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-07-14       Impact factor: 4.310

7.  Poly(ADP-ribose) polymerase (PARP) inhibition counteracts multiple manifestations of kidney disease in long-term streptozotocin-diabetic rat model.

Authors:  Hanna Shevalye; Roman Stavniichuk; Weizheng Xu; Jie Zhang; Sergey Lupachyk; Yury Maksimchyk; Viktor R Drel; Elizabeth Z Floyd; Barbara Slusher; Irina G Obrosova
Journal:  Biochem Pharmacol       Date:  2009-11-27       Impact factor: 5.858

8.  Delivery of antioxidant enzyme genes to protect against ischemia/reperfusion-induced injury to retinal microvasculature.

Authors:  Baihua Chen; Sergio Caballero; Soojung Seo; Maria B Grant; Alfred S Lewin
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-07-23       Impact factor: 4.799

9.  Extracellular SOD and VEGF are increased in vitreous bodies from proliferative diabetic retinopathy patients.

Authors:  Hiroshi Izuta; Yuichi Chikaraishi; Tetsuo Adachi; Masamitsu Shimazawa; Tetsuya Sugiyama; Tsunehiko Ikeda; Hideaki Hara
Journal:  Mol Vis       Date:  2009-12-10       Impact factor: 2.367

10.  Vaccinium myrtillus (Bilberry) Extracts Reduce Angiogenesis In Vitro and In Vivo.

Authors:  Nozomu Matsunaga; Yuichi Chikaraishi; Masamitsu Shimazawa; Shigeru Yokota; Hideaki Hara
Journal:  Evid Based Complement Alternat Med       Date:  2007-10-27       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.